Active, not recruitingPhase 2NCT05309616
Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
Studying Idiopathic subglottic stenosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yale University
- Principal Investigator
- Nwanmegha Young, MD, MDYale University
- Intervention
- Taltz(drug)
- Enrollment
- 10 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Yale New Haven Hospital, New Haven, Connecticut, United States
Collaborators
Lilly PharmaceuticalCompany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05309616 on ClinicalTrials.gov